Decades of research on AD have recognized novel drug targets for the therapeutic intervention, the most promising among them is DYRK1A (dual-specificity tyrosine phosphorylation-regulated kinase 1A) [7,8,9,10]. This evidence concerns the gene DYRK1A and Alzheimer disease.